REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024. Starting at 5:00 p.m. EDT on August 8, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.
Conference Call Information
When: Thursday, August 8, 2024, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register here to receive dial-in information and a personal PIN to access the live call.
Please dial in 15 minutes early to ensure a timely connection to the call.
Webcast: https://edge.media-server.com/mmc/p/kguryzuk
The press release with the second quarter 2024 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.
A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.
Disclosure Information
Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
Coherus Contact Information
Investors:
Jami Taylor, Head of Investor Relations for Coherus
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.87 |
| Daily Change: | -0.0012 -0.14 |
| Daily Volume: | 1,114,783 |
| Market Cap: | US$100.510M |
May 12, 2025 March 10, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
